Innate Pharma S.A. (EPA: IPH)

Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	69.99	70.61	84.23	103.76	136.79	202.89
Short-Term Investments	21.81	21.85	17.26	16.08	14.85	15.98
Cash & Short-Term Investments	91.8	92.46	101.49	119.84	151.64	218.87
Cash Growth	3.27%	-8.90%	-15.31%	-20.97%	-30.72%	30.64%
Accounts Receivable	0.39	15.23	3.08	0.85	10.59	2.82
Other Receivables	13.44	31.26	27.94	12.63	3.28	10.32
Receivables	13.83	46.49	31.02	13.47	13.87	13.14
Prepaid Expenses	3.01	5.69	4.67	2.58	6.83	5.4
Other Current Assets	2.96	3.37	2.65	2.36	1.11	0.2
Total Current Assets	111.59	148.01	139.83	138.26	173.45	237.61
Property, Plant & Equipment	5.75	6.32	8.54	10.17	11.69	11.67
Long-Term Investments	10.35	9.8	35.12	39.88	38.93	37.01
Other Intangible Assets	0.12	0.42	1.56	44.19	46.29	96.97
Long-Term Deferred Tax Assets	9.12	9.01	8.57	5.03	7.09	1.29
Other Long-Term Assets	14.56	10.64	14.25	29.97	29.97	16.83
Total Assets	151.5	184.19	207.86	267.5	307.42	401.36
Accounts Payable	8.75	8.56	13.66	14.73	20.73	27.94
Current Portion of Long-Term Debt	8.51	8.45	1.28	29.94	1.37	1.49
Current Portion of Leases	0.42	0.49	0.82	0.8	0.78	0.64
Current Income Taxes Payable	6.01	7.02	5.98	7.46	8.33	7
Current Unearned Revenue	13.05	13.51	16.78	19.92	13.13	70.07
Other Current Liabilities	1.48	1.61	2.82	7.03	1.16	14.68
Total Current Liabilities	38.22	39.64	41.34	79.89	45.49	121.82
Long-Term Debt	26.41	30.61	38.93	11.49	14.19	14.1
Long-Term Leases	0.16	0.35	1.22	2.01	2.76	2.49
Long-Term Unearned Revenue	46.02	49.65	60.91	58.41	77.53	40.34
Long-Term Deferred Tax Liabilities	9.12	9.01	8.57	5.03	7.09	1.29
Other Long-Term Liabilities	0.29	0.6	0.2	0.25	0.22	0.14
Total Liabilities	122.7	132.29	153.71	160.06	151.45	183.95
Common Stock	4.05	4.04	4.01	3.98	3.95	3.94
Additional Paid-In Capital	386.05	384.26	379.64	375.22	372.13	369.62
Retained Earnings	-361.66	-336.89	-330.32	-272.21	-220.46	-155.67
Comprehensive Income & Other	0.36	0.5	0.82	0.46	0.36	-0.47
Shareholders' Equity	28.8	51.9	54.15	107.44	155.98	217.42
Total Liabilities & Equity	151.5	184.19	207.86	267.5	307.42	401.36
Total Debt	35.5	39.89	42.25	44.25	19.09	18.72
Net Cash (Debt)	56.3	52.56	59.23	75.59	132.55	200.14
Net Cash Growth	16.72%	-11.26%	-21.63%	-42.98%	-33.77%	22.78%
Net Cash Per Share	0.70	0.65	0.74	0.95	1.68	2.99
Filing Date Shares Outstanding	80.95	80.86	80.19	79.54	78.98	78.81
Total Common Shares Outstanding	80.95	80.86	80.19	79.54	78.98	78.81
Working Capital	73.37	108.38	98.49	58.37	127.96	115.78
Book Value Per Share	0.36	0.64	0.68	1.35	1.97	2.76
Tangible Book Value	28.68	51.49	52.6	63.25	109.69	120.45
Tangible Book Value Per Share	0.35	0.64	0.66	0.80	1.39	1.53

Source: S&P Capital IQ. Standard template. Financial Sources.